PMID- 31202431
OWN - NLM
STAT- MEDLINE
DCOM- 20200213
LR  - 20200213
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Linking)
VI  - 56
IP  - 3
DP  - 2019 Jul
TI  - Is human leukocyte antigen-matched sibling donor transplant always better than 
      haploidentical allograft?
PG  - 201-208
LID - S0037-1963(18)30115-X [pii]
LID - 10.1053/j.seminhematol.2018.07.005 [doi]
AB  - Currently, haploidentical donor has been an alternative source of stem cell 
      allografts for patients who have no human leukocyte antigen-matched sibling donor 
      or unrelated donors. A number of studies indicated that treating hematological 
      malignancy patients with haploidentical stem cell transplantation (haplo-SCT) 
      could achieve comparable outcomes to those who underwent matched sibling donor 
      transplantation (MSDT). In recent years, more and more evidence support the 
      notion that haploidentical allografts may have a stronger graft-vs-leukemia (GVL) 
      effect than MSDT. In this review, we summarized the transplant outcomes of 
      haplo-SCT and MSDT, mainly focusing on the subgroup of patients who will benefit 
      from the stronger GVL effects of haplo-SCT compared with MSDT. We also offered 
      strategies of how to translate the strong antileukemia activity of haploidentical 
      allograft into superior survival. Future directions of GVL effects in haplo-SCT 
      settings were also discussed.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Xicheng District, Beijing, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Xicheng District, Beijing, China; Peking-Tsinghua Center for Life Sciences, 
      Beijing, China. Electronic address: xjhrm@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180823
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Allografts/*transplantation
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Siblings
MH  - Tissue Donors
MH  - Transplantation, Haploidentical/*methods
OTO - NOTNLM
OT  - Graft-vs-leukemia effects
OT  - Haploidentical stem cell transplantation
OT  - Human leukocyte antigen-matched sibling donor transplantation
EDAT- 2019/06/17 06:00
MHDA- 2020/02/14 06:00
CRDT- 2019/06/17 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/07/27 00:00 [accepted]
PHST- 2019/06/17 06:00 [entrez]
PHST- 2019/06/17 06:00 [pubmed]
PHST- 2020/02/14 06:00 [medline]
AID - S0037-1963(18)30115-X [pii]
AID - 10.1053/j.seminhematol.2018.07.005 [doi]
PST - ppublish
SO  - Semin Hematol. 2019 Jul;56(3):201-208. doi: 10.1053/j.seminhematol.2018.07.005. 
      Epub 2018 Aug 23.